Navigation Links
NYSCF and NIH create cell models of rare and undiagnosed diseases
Date:11/21/2013

NEW YORK, NY (November 21, 2013) In what is anticipated to be a major step forward for rare disease research, The New York Stem Cell Foundation (NYSCF) Research Institute is partnering with the National Institutes of Health (NIH) Undiagnosed Disease Program (UDP). NYSCF scientists will generate stem cell lines from 100 patients in the UDP and collaborate with UDP researchers to better understand and potentially treat select rare diseases. While working collaboratively under this agreement, neither NIH nor NYSCF will receive funding. This partnership will leverage investments made using government (NIH) and private (NYSCF) dollars to ensure that research into rare diseases will move forward efficiently and effectively.

In 2008, the NIH developed the UDP to study patients with rare diseases, track their progression and symptoms, and obtain biological specimen samples to help pinpoint the root cause of their ailments. These patients, whose disorders have long-eluded diagnosis, provide skin samples that will be used to generate stem cell lines on the NYSCF Global Stem Cell Array, a robotic technology that automates the derivation process. "The NYSCF Global Stem Cell Array provides us with the critical ability to produce accurate cell models of these rare diseases, serving as 'windows onto disease,'" said Susan L. Solomon, CEO of NYSCF.

"This collaborative effort has the potential to create new disease models that will reveal whether candidate gene variants are responsible for a patient's disease," said Dr. William Gahl, Director of the NIH UDP. "In addition, the stem cells can illustrate new mechanisms with broad applicability to more common disorders." Gahl also noted that this venture may eventually be expanded to other centers within the Undiagnosed Diseases Network. The network is a group of 5 to 7 clinical sites, in addition to the UDP, that the NIH Common Fund will establish within the coming year.

NYSCF scientists will create
'/>"/>

Contact: David McKeon
dmckeon@nyscf.org
212-365-7440
New York Stem Cell Foundation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. NYSCF scientists develop 3-D stem cell culture technique to better understand Alzheimers disease
2. NYSCF scientists develop new protocol to ready induced pluripotent stem cell clinical application
3. President, CEO Leppävuori, VTT: Finland should create a national bioeconomy strategy
4. Scientists discover switch in plants to create flowers
5. Climate change may create price volatility in the corn market, say Stanford and Purdue researchers
6. Putting plants online: 4 leading botanical gardens to create first online catalog of all plants
7. Botanical institutions announce plans to create first online World Flora
8. Engineers use droplet microfluidics to create glucose-sensing microbeads
9. U-M biologist plays key role in effort to create first comprehensive tree of life
10. University of Hawaii Cancer Center researchers create new anti-cancer drug
11. A non-invasive intracellular thermometer with fluorescent proteins has been created
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2015)... , Feb. 24, 2015 Research and Markets ... addition of the "Global 2D Gesture Recognition ... The analysts forecast the Global 2D ... of 32.12% over the period 2014-2019 ... non-traditional sectors is one of the major trends ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
... long looked to the future when a damaged heart could ... A study published in the February issue of Circulation ... that heart stem cells from children with congenital heart disease ... Sunjay Kaushal, MD, PhD, surgeon ...
... the field of cardiac therapeutics have long looked to the ... by using one,s own heart cells. A study published in ... of the American Heart Association, shows that heart stem cells ... the damaged heart in an animal model. ...
... scientist is digging deep to solidify information about potential ... Tungsten is a naturally occurring metallic element that in ... incandescent lightbulb filaments and X-ray tubes. In an ... replacing lead in fishing weights and in ammunition for ...
Cached Biology News:Stem cells show promise in repairing a child's heart 2Using a child's own stem cells to repair their heart looks promising 2National study explores the reaction and transport of tungsten in drinking water 2
(Date:3/5/2015)... Plant disease specialists from around the ... Annual Meeting of The American Phytopathological Society. Details ... now at APSnet.org/meet . , The Preliminary Daily ... be held August 1-5, 2015 in Pasadena, California, U.S.A. ... Workshops, and committee meetings, all carefully balanced to deliver ...
(Date:3/5/2015)... Bi-Biomics today announced a discovery made ... The improvement in histological quality provided the detail ... all daughter cells. , After processing with Ultralight ... at 1000-1600x using light microscopy. Phylogenetic and ... daughter cells displayed predominant binary features --- one ...
(Date:3/5/2015)... TORONTO , March 5, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... G. Rice , Ph.D., Chairman, President and Chief Executive ... Conference on Tuesday, March 10 th at 9:30 ... Laguna Niguel, CA. Dr. Rice will provide ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research and ... addition of the "Mature Biotech Outlook 2015: New ... to their offering. All biotech companies ... Celgene (CELG), in past year, have given a positive ... These companies have been able to select therapy/niche indication ...
Breaking Biology Technology:American Phytopathological Society Announces Annual Meeting Daily Schedule 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3
... Elbit Medical,Imaging Ltd. (Nasdaq: EMITF ) ("EMI") today ... has entered into definitive agreements,with one of the leading ... of a large scale mixed-use project located in,Bangalore, Karnataka, ... an Indian company to be,held in equal parts by ...
... PRINCETON, N.J., Oct. 22 Pharmacopeia,(Nasdaq: PCOP ), ... molecule therapeutics, today announced that Dr. Leslie J. Browne,President ... the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare,Conference. ... 2007, at the New,York Palace Hotel in New York ...
... Boston,Scientific Corporation (NYSE: BSX ) today ... from its TAXUS ARRIVE 1 and 2 registries, ... Paclitaxel-Eluting,Coronary Stent System in "real-world" practice. The pooled ... and repeat,revascularization through two years in complex patients ...
Cached Biology Technology:Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India 2Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India 3Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India 4Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 4ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... primers are designed for sequencing inserts cloned ... T7, or T3 RNA polymerase promoters, or ... supplied at a concentration of 0.1 µg/µl ... in DNA sequencing reactions using SequiTherm™ EXCEL™ ...
Biology Products: